Iyar 5786: Let My People Heal — Why Jews Should Seek Legal Psychedelic Care Right Now
There is a particular kind of exhaustion that has settled into Jewish life in America. It did not begin on October 7th, though that day cracked something open that has not closed. It began earlier — in the isolation of COVID, in the fracturing of communities that had not yet recovered from that rupture when the next one arrived, in the slow and grinding effort to hold Jewish life together while forces on every side worked to pull it apart. And longer ago still — in historic wounds that silently shape our individual and communal lives in ways most of us have never had the tools to name, let alone heal.
It lives in the bodies of rabbis who have not slept well in years. In the group chats of Jewish college students navigating harassment and isolation. In the silence of families who no longer know how to talk about Israel. In the exhaustion of Jewish activists who have watched their allies turn on and abandon them. In the loneliness of Jews who feel they have no political home at all.
The tools most of us reach for — therapy, prayer, community, distraction — are struggling to meet it.
There is something else available. It is not new. In some sense, it is ancient. And for the first time in American history, you can access it legally — if you know where to look.
The legal landscape is shifting—quickly
On April 18th, the White House signed an executive order directing the FDA to accelerate review of psychedelic therapies with Breakthrough Therapy designation, allocating $50 million in federal matching funds for state research programs, and instructing the FDA and DEA to build an access pathway for investigational compounds including ibogaine. It is the first federal action affirmatively moving psychedelic medicine toward the mainstream of American healthcare.
Psilocybin is already legal for therapeutic use in Oregon and Colorado, where licensed healing centers have served more than 10,000 clients. New Mexico legalized medical psilocybin in 2025. Ketamine is available through licensed providers in most states. Compass Pathways has completed two successful Phase 3 trials for treatment-resistant depression, with a potential FDA approval decision by late 2026 or early 2027 — which would make it the first classic psychedelic ever approved.
The clinical data is striking. Psilocybin has shown significant reductions in treatment-resistant depression, PTSD, and end-of-life anxiety at Johns Hopkins, NYU, and UCSF, often after a single session. Stanford researchers published a landmark study in Nature Medicine documenting dramatic reductions in PTSD, depression, and suicidal ideation in Special Operations veterans after a single ibogaine session — findings compelling enough that Texas recently allocated $50 million for ibogaine trials. At Mount Sinai, Dr. Rachel Yehuda — a pioneer in studying the biological transmission of trauma through Holocaust survivor families — is running psilocybin trials specifically targeting intergenerational trauma. The wounds Jews carry across generations are not metaphorical. They are biological, epigenetic, and finally being taken seriously as a target for healing.
We have always known this
Judaism is not a stranger to altered states. The Torah describes the Sinai revelation as a synaesthetic event — the people saw the thunder, heard the fire. The Kabbalists mapped the soul’s capacity for expansion and contraction, for dissolution and return, with a precision that reads today like a phenomenology of psychedelic experience.
The Piaseczner Rebbe, writing in Warsaw in the 1930s, taught that the soul requires genuine emotional and spiritual arousal for psychological health. Without it, he wrote, a person will either seek cheap substitutes or eventually suffer mental illness. He was describing trauma, dissociation, and the slow erosion of meaning — and he was describing, with remarkable precision, what is happening in American Jewish life right now.
The crisis belongs to all of us
Antisemitic incidents reached record levels in 2023 and continued rising in 2024. Jewish students report feeling unsafe and politically homeless. Jewish activists across every political camp have watched their allies fail them, discovering that solidarity has conditions none of them agreed to. Jewish leaders are burning out. Jewish young adults are disengaging with a speed that has alarmed every major institution. And beneath all of it runs something older — the ancestral weight of a people that carries trauma encoded not just in memory but in the body.
This is a communal mental health crisis. It belongs to the whole community, not to any faction. And it deserves interventions equal to its depth.
What the data shows
In the first large-scale study of Jewish psychedelic experience, conducted with Emory University, we heard from over 1,100 Jewish people — the majority unaffiliated or underserved by Jewish institutions. Among them, 88% had already tried psychedelics. More than a third had done so specifically to address intergenerational trauma. 69% reported increased connection to the divine. And yet for most, these experiences did not feel Jewish — not because Judaism had nothing to offer, but because no one had brought it into the room.
Psychedelic experiences increased curiosity about Jewish identity, interest in Jewish ritual and practice, and a sense that Judaism could feel personally relevant — among people who had largely walked away from communal life. These are not people who are done with Judaism. They are people Judaism has not yet found a way to reach.
Why Jewish psychedelic care
When a Jewish person in a psilocybin session encounters ancestral trauma, questions of God’s presence or absence, the weight of collective memory — a clinician trained only in Western therapeutic models may not know how to hold and support what emerges.
The journey itself is only the beginning. What happens afterward — the slow work of metabolizing, meaning-making, and weaving the experience back into a life — is where healing takes root. This is what the tradition calls teshuvah, return. And it is where Jewish wisdom has the most to offer. A small but serious ecosystem of Jewishly rooted, licensed practitioners is building the containers for exactly this work.
A word of honest caution
The growing visibility of psychedelic healing has attracted opportunists alongside serious practitioners. Would-be shamans with weekend certifications, underground ceremonies with no safety protocols, facilitators whose credentials are self-declared — these exist and cause harm. Sexual boundary violations are a documented problem. This is precisely why licensed, regulated frameworks matter. Ask about training, credentials, and legal compliance. Ask whether the container is built for your safety or for someone else’s spiritual ego. A trustworthy practitioner will welcome those questions. Psychedelics are also not for everyone — they are contraindicated for certain conditions and require careful screening.
An invitation
We are in the month of Iyar — the month the tradition has always associated with healing. Its letters form an acronym for Ani Adonai Rofecha — I am the Lord your healer — the promise God makes to Israel at Marah, where bitter wood made bitter water sweet. We have the same opportunity now: to turn our adversaries into allies, our wounds into wisdom.
Jeremiah cried to God: Heal me, and I will be healed. Save me, and I will be saved. The rabbis asked: if God heals, what does “and I will be healed” add? The answer embedded in the grammar is that healing requires a particular posture — placing oneself in a state of genuine receptivity, open to being transformed at a depth the ordinary mind cannot reach alone.
That is what psychedelic care, at its best, makes possible. And that is what the Jewish tradition, at its deepest, has always been pointing toward.
The weight is carried in bodies. The exhaustion has names and faces. Jewish communities across America are carrying more than they know how to process through ordinary means.
Iyar has always called us to heal. The bitter medicine is now within reach.
